JP2023505303A - 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法 - Google Patents

癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法 Download PDF

Info

Publication number
JP2023505303A
JP2023505303A JP2022534242A JP2022534242A JP2023505303A JP 2023505303 A JP2023505303 A JP 2023505303A JP 2022534242 A JP2022534242 A JP 2022534242A JP 2022534242 A JP2022534242 A JP 2022534242A JP 2023505303 A JP2023505303 A JP 2023505303A
Authority
JP
Japan
Prior art keywords
agonist
dose
body weight
combination
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505303A5 (https=
Inventor
エヴェリーン，スミッツ
ジョナス，バナウデナエルデ
マルク，ぺーテルス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Original Assignee
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIVERSITAIR ZIEKENHUIS ANTWERPEN filed Critical UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Publication of JP2023505303A publication Critical patent/JP2023505303A/ja
Publication of JP2023505303A5 publication Critical patent/JP2023505303A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022534242A 2019-12-06 2020-12-04 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法 Pending JP2023505303A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214049.9 2019-12-06
EP19214049 2019-12-06
PCT/EP2020/084665 WO2021110930A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Publications (2)

Publication Number Publication Date
JP2023505303A true JP2023505303A (ja) 2023-02-08
JP2023505303A5 JP2023505303A5 (https=) 2023-11-17

Family

ID=68808124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534242A Pending JP2023505303A (ja) 2019-12-06 2020-12-04 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法

Country Status (8)

Country Link
US (1) US20220411524A1 (https=)
EP (1) EP4069739A1 (https=)
JP (1) JP2023505303A (https=)
CN (1) CN115052891A (https=)
AU (1) AU2020395907A1 (https=)
CA (1) CA3163777A1 (https=)
IL (1) IL293613A (https=)
WO (1) WO2021110930A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523181A (ja) * 2021-06-03 2024-06-28 アペクシジェン アメリカ， インコーポレイテッド Ｃｄ－４０アゴニストを用いてがんを処置する方法
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"ANTI-TUMOURAL EFFECTS OF IL-15 AND CD40 STIMULATION AS A NOVEL COMBINATION IMMUNOTHERAPY FOR PANCREA", ESMO OPEN, vol. Vol.3, Suppl.2, pp.A393-394, PO-417, JPN6024042421, 2018, ISSN: 0005546778 *
PROC. NATL. ACAD. SCI. USA, vol. Vol.106, No.18, pp.7513-7518, JPN6024042420, 2009, ISSN: 0005546779 *
THE JOURNAL OF IMMUNOLOGY, vol. Vol.188, pp.6156-6164, JPN6024042419, 2012, ISSN: 0005546780 *

Also Published As

Publication number Publication date
IL293613A (en) 2022-08-01
US20220411524A1 (en) 2022-12-29
WO2021110930A1 (en) 2021-06-10
EP4069739A1 (en) 2022-10-12
CA3163777A1 (en) 2021-06-10
AU2020395907A1 (en) 2022-07-21
CN115052891A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP6416926B2 (ja) ガン標的化ｉｌ−１２免疫療法
US11224611B2 (en) Immune modulation with TLR9 agonists for cancer treatment
JP2019065028A (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
TW202428301A (zh) 治療性rna
Mitchell Immunotherapy as part of combinations for the treatment of cancer
US20240033257A1 (en) Use of ppar-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug
US20200377596A1 (en) Dosing of bispecific t cell engager
JP2023505303A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法
CN108815188A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
Tang et al. Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice
Gong et al. Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy
JP2023551733A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの併用免疫療法
TW202304512A (zh) 雙特異性t細胞銜接體之給藥
JP2023512487A (ja) 癌を治療するための投与養生法および方法
US20240010740A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
Nakano et al. Intravenous administration of MIP-1α with intra-tumor injection of P. acnes shows potent anti-tumor effect
KR20200116112A (ko) 화학요법에 순차적인 수지상 세포 백신접종

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909